They also suggested that the use of PCSK9 inhibitors significantly reduced the risk of MI, ischemic stroke, and coronary revascularization in patients with dyslipidemia or atherosclerotic cardiovascular disease. This evidence concerns the gene PCSK9 and ischemic stroke.